Jayesh Sanmukhani

501 total citations · 1 hit paper
10 papers, 319 citations indexed

About

Jayesh Sanmukhani is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Jayesh Sanmukhani has authored 10 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 3 papers in Infectious Diseases and 2 papers in Health. Recurrent topics in Jayesh Sanmukhani's work include Respiratory viral infections research (4 papers), Influenza Virus Research Studies (3 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Jayesh Sanmukhani is often cited by papers focused on Respiratory viral infections research (4 papers), Influenza Virus Research Studies (3 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Jayesh Sanmukhani collaborates with scholars based in India, United Arab Emirates and Taiwan. Jayesh Sanmukhani's co-authors include Kevinkumar Kansagra, Ayan Dey, Parshottam Koradia, Krishna Giri, Rajnish Nagarkar, Shrikant Deshpande, Kapil Maithal, Bhumika Sharma, Sunil Sharma and Jatin Patel and has published in prestigious journals such as The Lancet, Human Vaccines & Immunotherapeutics and EClinicalMedicine.

In The Last Decade

Jayesh Sanmukhani

9 papers receiving 302 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

2022 151 citations Shrikant Deshpande, Krishna Giri et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jayesh Sanmukhani India	7	215	104	79	76	36	10	319
Ikbel Hadj Hassine Tunisia	5	213 1.0×	73 0.7×	40 0.5×	38 0.5×	41 1.1×	7	312
Limor Kliker Israel	10	247 1.1×	54 0.5×	49 0.6×	28 0.4×	40 1.1×	27	306
Ital Nemet Israel	10	232 1.1×	51 0.5×	48 0.6×	26 0.3×	60 1.7×	24	296
Bosco Lam China	4	262 1.2×	48 0.5×	38 0.5×	23 0.3×	19 0.5×	6	298
Yuqian Yan China	7	152 0.7×	64 0.6×	24 0.3×	27 0.4×	44 1.2×	11	243
Chunke Chen China	9	415 1.9×	158 1.5×	78 1.0×	64 0.8×	75 2.1×	16	525
Sandra Hauka Germany	5	406 1.9×	61 0.6×	66 0.8×	39 0.5×	35 1.0×	7	473
Biliana Nestorova United States	3	231 1.1×	62 0.6×	61 0.8×	45 0.6×	19 0.5×	3	272
Duncan Cook United Kingdom	4	334 1.6×	41 0.4×	123 1.6×	20 0.3×	41 1.1×	5	413
Kwok Yung Yuen Hong Kong	4	285 1.3×	51 0.5×	39 0.5×	29 0.4×	19 0.5×	6	336

Countries citing papers authored by Jayesh Sanmukhani

Since Specialization

Citations

This map shows the geographic impact of Jayesh Sanmukhani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayesh Sanmukhani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayesh Sanmukhani more than expected).

Fields of papers citing papers by Jayesh Sanmukhani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayesh Sanmukhani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayesh Sanmukhani. The network helps show where Jayesh Sanmukhani may publish in the future.

Co-authorship network of co-authors of Jayesh Sanmukhani

This figure shows the co-authorship network connecting the top 25 collaborators of Jayesh Sanmukhani. A scholar is included among the top collaborators of Jayesh Sanmukhani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayesh Sanmukhani. Jayesh Sanmukhani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Kothari, Kunal, Shreyansh Shah, V J Gill, et al.. (2024). A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months. Human Vaccines & Immunotherapeutics. 20(1). 2416329–2416329.

Jain, Manish Kumar, et al.. (2022). Efficacy and Safety of Fluticasone Furoate and Oxymetazoline Nasal Spray: A Novel First Fixed Dose Combination for the Management of Allergic Rhinitis with Nasal Congestion. Journal of Asthma and Allergy. Volume 15. 783–792. 7 indexed citations

Deshpande, Shrikant, Krishna Giri, Rajnish Nagarkar, et al.. (2022). Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. The Lancet. 399(10332). 1313–1321. 151 indexed citations breakdown →

Kumar, Manish, et al.. (2022). Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: A randomized, double blind, multicenter clinical trial. International Journal of Urology. 29(4). 351–359. 14 indexed citations

Kansagra, Kevinkumar, Sunil Sharma, Bhumika Sharma, et al.. (2021). Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine. 38. 101020–101020. 121 indexed citations

Sarkar, Sumantra, et al.. (2020). Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial. Human Vaccines & Immunotherapeutics. 17(3). 681–689. 2 indexed citations

Joshi, Rajesh K., et al.. (2018). Immunogenicity and Safety of a Novel MMR Vaccine (Live) (Freeze-dried): Results of a Phase II Clinical Trial. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 1 indexed citations

Kumar, Sanjay, et al.. (2018). Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial. Human Vaccines & Immunotherapeutics. 14(6). 1362–1369. 7 indexed citations

Sood, Ashwani, et al.. (2017). Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial. Human Vaccines & Immunotherapeutics. 13(7). 1523–1530. 9 indexed citations

10.

Sanmukhani, Jayesh, et al.. (2014). Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience. South Asian Journal of Cancer. 3(2). 132–137. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact